

| | |
|---|-------|
| CHAPTER ONE: INTRODUCTION..... | 1 |
| STUDY GOALS AND OBJECTIVES..... | 1 |
| REASONS FOR DOING THE STUDY | 1 |
| CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE..... | 2 |
| SCOPE OF REPORT | 2 |
| METHODOLOGY AND INFORMATION SOURCES..... | 2 |
| ANALYST CREDENTIALS..... | 3 |
| RELATED REPORTS..... | 3 |
| BCC ON-LINE SERVICES..... | 4 |
| DISCLAIMER | 4 |
| CHAPTER TWO: SUMMARY..... | 5 |
| SUMMARY..... | 5 |
| <i>SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS</i> <i>MARKET, THROUGH 2016 (\$ MILLIONS)</i> | 6 |
| <i>SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS</i> <i>MARKET, 2009-2016 (\$ MILLIONS)</i> | 7 |
| CHAPTER THREE: OVERVIEW | 8 |
| DEFINITIONS | 8 |
| STRUCTURE OF ENZYMES..... | 8 |
| ACTIVATION ENERGY..... | 8 |
| SPECIFICITY | 9 |
| ENZYME SUBSTRATE INTERACTION | 9 |
| CONDITIONS OF ENZYME ACTION | 9 |
| CLASSIFICATION OF ENZYMES..... | 10 |
| OXIDOREDUCTASES..... | 10 |
| TRANSFERASES..... | 11 |
| HYDROLASES | 11 |
| Nucleases | 12 |
| Phosphatases | 12 |
| LYASES | 12 |
| ISOMERASES..... | 12 |
| LIGASES | 13 |
| REAL-LIFE APPLICATIONS OF ENZYMES..... | 13 |
| METABOLIC ENZYMES..... | 14 |
| DIGESTIVE ENZYMES | 15 |
| FOOD ENZYMES..... | 16 |
| NEED FOR ENZYMES IN HUMAN BODY..... | 16 |
| PROTEOLYTIC ENZYMES | 17 |
| LIPOLYTIC ENZYMES | 17 |
| AMYLOLYTIC ENZYMES | 17 |
| RENNIN ENZYMES..... | 18 |
| WHAT ARE ENZYME INHIBITORS | 18 |

| | |
|--|-----------|
| WHY ENZYME INHIBITION..... | 18 |
| USE OF ENZYME INHIBITORS..... | 19 |
| MECHANISM OF ENZYME INHIBITION..... | 19 |
| TYPES OF ENZYME INHIBITORS | 20 |
| MIXED INHIBITION..... | 20 |
| COMPETITIVE INHIBITION..... | 20 |
| CLASSIFICATION OF ENZYME INHIBITORS | 21 |
| <i>TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS.....</i> | <i>21</i> |
| OXIDOREDUCTASE INHIBITORS | 22 |
| Aldose Reductase Inhibitors..... | 22 |
| Statins..... | 22 |
| History of Development of Statins | 23 |
| <i>TABLE 2 HISTORY OF DEVELOPMENT OF STATINS</i> | <i>23</i> |
| 5-Alpha-Reductase Inhibitors | 23 |
| Aromatase Inhibitors..... | 23 |
| COX-2 Inhibitors | 24 |
| HYDROLASE INHIBITORS | 24 |
| Neuraminidase Inhibitors | 24 |
| Protease Inhibitors | 25 |
| <i>TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS</i> | <i>25</i> |
| Phosphodiesterase Type 5 (PDE5) Inhibitors | 26 |
| Phosphodiesterase Type 4 (PDE4) Inhibitors | 26 |
| Angiotensin-Converting Enzyme (ACE) Inhibitors | 27 |
| <i>TABLE 4 DEVELOPMENT OF ACE INHIBITORS</i> | <i>27</i> |
| Proton Pump Inhibitors..... | 28 |
| TRANSFERASE INHIBITORS | 28 |
| Protein Kinase Inhibitors..... | 28 |
| Reverse Transcriptase Inhibitors | 29 |
| CHAPTER FOUR: REGULATORY ASPECTS | 30 |
| <i>TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008–</i> | |
| <i>2011.....</i> | <i>30</i> |
| <i>TABLE 5 (CONTINUED).....</i> | <i>31</i> |
| <i>TABLE 5 (CONTINUED).....</i> | <i>32</i> |
| <i>TABLE 5 (CONTINUED).....</i> | <i>33</i> |
| <i>TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS</i> | <i>34</i> |
| <i>TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008–2011.....</i> | <i>35</i> |
| <i>TABLE 7 (CONTINUED).....</i> | <i>36</i> |
| <i>TABLE 7 (CONTINUED).....</i> | <i>37</i> |
| CHAPTER FIVE: MARKET LEADERS AND THEIR PRODUCTS FOR | |
| ENZYME INHIBITORS..... | 38 |
| <i>TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON</i> | |
| <i>PUMP INHIBITORS</i> | <i>38</i> |

| | |
|---|--------|
| <i>TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS</i> | 38 |
| <i>TABLE 9 (CONTINUED)</i> | 39 |
| <i>TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS</i> | 39 |
| <i>TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS</i> | 40 |
| <i>TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS</i> | 40 |
| <i>TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS</i> | 41 |
| <i>TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS</i> | 42 |
| <i>TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS</i> | 42 |
| <i>TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS</i> | 42 |
| <i>TABLE 16 (CONTINUED)</i> | 43 |
| CHAPTER SIX: NEW DEVELOPMENTS | 44 |
| <i>TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS</i> | 44 |
| <i>TABLE 17 (CONTINUED)</i> | 45 |
| <i>TABLE 18 CLINICAL TRIALS OF STATINS</i> | 45 |
| <i>TABLE 18 (CONTINUED)</i> | 46 |
| <i>TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS</i> | 47 |
| <i>TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS</i> | 47 |
| <i>TABLE 20 (CONTINUED)</i> | 48 |
| <i>TABLE 20 (CONTINUED)</i> | 49 |
| <i>TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS</i> | 49 |
| <i>TABLE 21 (CONTINUED)</i> | 50 |
| <i>TABLE 21 (CONTINUED)</i> | 51 |
| <i>TABLE 21 (CONTINUED)</i> | 52 |
| <i>TABLE 21 (CONTINUED)</i> | 53 |
| <i>TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS</i> | 54 |
| <i>TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS</i> | 54 |
| <i>TABLE 23 (CONTINUED)</i> | 55 |
| <i>TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS</i> | 55 |
| <i>TABLE 24 (CONTINUED)</i> | 56 |
| <i>TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS</i> | 56 |
| <i>TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS</i> | 57 |
| NEW DRUGS IN CLINICAL TRIALS..... | 58 |
| <i>TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS</i> | 58 |
| CHAPTER SEVEN: GLOBAL MARKETS | 59 |
| MARKET ANALYSIS | 59 |

| | |
|--|----|
| <i>TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 60 |
| <i>FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 61 |
| PROTON PUMP INHIBITORS | 61 |
| Market Overview | 62 |
| Market Revenue | 63 |
| <i>TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 64 |
| <i>FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 64 |
| PROTEASE INHIBITORS | 64 |
| Market Overview | 65 |
| Market Revenue | 66 |
| <i>TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 67 |
| <i>FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 67 |
| REVERSE TRANSCRIPTASE INHIBITORS..... | 67 |
| Market Overview | 68 |
| Market Overview (Continued)..... | 69 |
| Market Revenue | 70 |
| <i>TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 70 |
| <i>FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 71 |
| KINASE INHIBITORS | 71 |
| Market Overview | 72 |
| Market Overview (Continued)..... | 73 |
| Market Revenue | 74 |
| <i>TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 74 |
| <i>FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 75 |
| STATINS | 75 |
| Market Overview | 76 |
| Market Revenue | 77 |
| <i>TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 (\$ MILLIONS)</i> | 78 |
| <i>FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 (\$ MILLIONS)</i> | 78 |
| AROMATASE INHIBITORS | 78 |
| Market Overview | 79 |
| Market Revenue | 80 |

| | |
|--|----|
| <i>TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 80 |
| <i>FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 81 |
| PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS | 81 |
| Market Overview | 82 |
| Market Revenue | 83 |
| <i>TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 83 |
| <i>FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 84 |
| NEURAMINIDASE INHIBITORS | 84 |
| Market Overview | 85 |
| Market Revenue | 85 |
| <i>TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 86 |
| <i>FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 86 |
| ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS | 86 |
| Market Overview | 87 |
| Market Revenue | 88 |
| <i>TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 88 |
| <i>FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 89 |
| MARKET SHARES | 89 |
| <i>TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 89 |
| <i>FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 90 |
| <i>TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 90 |
| <i>FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 91 |
| <i>TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 91 |
| <i>FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 92 |
| <i>TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 92 |
| <i>FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 93 |
| <i>TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 93 |

| | |
|--|-----|
| <i>FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 94 |
| <i>TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 94 |
| <i>FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 95 |
| <i>TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 95 |
| <i>FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 96 |
| <i>TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 96 |
| <i>FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 97 |
| <i>TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 97 |
| <i>FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%)</i> | 98 |
| <i>MARKET BY APPLICATIONS</i> | 98 |
| <i>TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH 2016 (\$ MILLIONS)</i> | 99 |
| <i>FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, 2009-2016 (\$ MILLIONS)</i> | 100 |
| <i>CARDIOVASCULAR (CV) DISEASE</i> | 100 |
| <i>Cardiovascular (CV) Disease (Continued)</i> | 101 |
| <i>TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016 (\$ MILLIONS)</i> | 102 |
| <i>FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016 (\$ MILLIONS)</i> | 103 |
| <i>GASTROINTESTINAL DISORDERS</i> | 103 |
| <i>TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016 (\$ MILLIONS)</i> | 104 |
| <i>FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016 (\$ MILLIONS)</i> | 105 |
| <i>ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)</i> | 105 |
| <i>Acquired Immunodeficiency ... (Continued)</i> | 106 |
| <i>TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 (\$ MILLIONS)</i> | 107 |
| <i>FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 (\$ MILLIONS)</i> | 107 |
| <i>HEPATITIS</i> | 108 |
| <i>TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 (\$ MILLIONS)</i> | 109 |
| <i>FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 (\$ MILLIONS)</i> | 109 |

| | |
|--|-----|
| CANCER..... | 110 |
| Cancer (Continued)..... | 111 |
| TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016 (\$ MILLIONS) | 112 |
| FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 (\$ MILLIONS)..... | 113 |
| ERECTILE DYSFUNCTION (ED) | 113 |
| TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016 (\$ MILLIONS) | 114 |
| FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016 (\$ MILLIONS)..... | 115 |
| OTHERS | 115 |
| TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 (\$ MILLIONS)..... | 116 |
| FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 (\$ MILLIONS)..... | 117 |
| GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION | 117 |
| TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) | 118 |
| FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%)..... | 118 |
| CHAPTER EIGHT: MARKETS IN THE UNITED STATES..... | 119 |
| MARKET ANALYSIS | 119 |
| TABLE 56 U.S. MARKET FOR ENZYME INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 120 |
| FIGURE 29 U.S. MARKET FOR ENZYME INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 121 |
| PROTON PUMP INHIBITORS (PPI) | 121 |
| Market Overview | 121 |
| Market Overview (Continued)..... | 122 |
| Market Revenue | 123 |
| TABLE 57 U.S. MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 123 |
| FIGURE 30 U.S. MARKET FOR PROTON PUMP INHIBITORS, 2009- 2016 (\$ MILLIONS)..... | 124 |
| PROTEASE INHIBITORS..... | 124 |
| Market Overview | 125 |
| Market Revenue | 126 |
| TABLE 58 U.S. MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 126 |
| FIGURE 31 U.S. MARKET FOR PROTEASE INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 127 |
| REVERSE TRANSCRIPTASE INHIBITORS..... | 127 |

| | |
|---|-----|
| Market Overview | 127 |
| Market Overview (Continued)..... | 128 |
| Market Revenue | 129 |
| <i>TABLE 59 U.S. MARKET FOR REVERSE TRANSCRIPTASE</i> | |
| <i>INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 129 |
| <i>FIGURE 32 U.S. MARKET FOR REVERSE TRANSCRIPTASE</i> | |
| <i>INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 129 |
| KINASE INHIBITORS | 130 |
| Market Overview | 130 |
| Market Overview (Continued)..... | 131 |
| Market Revenue | 132 |
| <i>TABLE 60 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016</i> | |
| <i>(\$ MILLIONS)</i> | 132 |
| <i>FIGURE 33 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 (\$</i> | |
| <i>MILLIONS)</i> | 132 |
| STATINS | 133 |
| Market Overview | 133 |
| Market Overview (Continued)..... | 134 |
| Market Revenue | 135 |
| <i>TABLE 61 U.S. MARKET FOR STATINS, THROUGH 2016 (\$</i> | |
| <i>MILLIONS)</i> | 135 |
| <i>FIGURE 34 U.S. MARKET FOR STATINS, 2009-2016 (\$ MILLIONS)</i> | 136 |
| AROMATASE INHIBITORS | 136 |
| Market Overview | 137 |
| Market Revenue | 137 |
| <i>TABLE 62 U.S. MARKET FOR AROMATASE INHIBITORS, THROUGH</i> | |
| <i>2016 (\$ MILLIONS)</i> | 138 |
| <i>FIGURE 35 U.S. MARKET FOR AROMATASE INHIBITORS, 2009-2016</i> | |
| <i>(\$ MILLIONS)</i> | 138 |
| PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS | 138 |
| Market Overview | 139 |
| Market Revenue | 140 |
| <i>TABLE 63 U.S. MARKET FOR PDE5 INHIBITORS, THROUGH 2016 (\$</i> | |
| <i>MILLIONS)</i> | 140 |
| <i>FIGURE 36 U.S. MARKET FOR PDE5 INHIBITORS, 2009-2016 (\$</i> | |
| <i>MILLIONS)</i> | 140 |
| NEURAMINIDASE INHIBITORS | 141 |
| Market Overview | 141 |
| Market Revenue | 141 |
| <i>TABLE 64 U.S. MARKET FOR NEURAMINIDASE INHIBITORS,</i> | |
| <i>THROUGH 2016 (\$ MILLIONS)</i> | 142 |
| <i>FIGURE 37 U.S. MARKET FOR NEURAMINIDASE INHIBITORS, 2009-</i> | |
| <i>2016 (\$ MILLIONS)</i> | 142 |
| ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS | 142 |

| | |
|--|-----|
| Market Overview | 143 |
| Market Revenue | 144 |
| <i>TABLE 65 U.S. MARKET FOR ACE INHIBITORS, THROUGH 2016 (\$</i> | |
| <i>MILLIONS)</i> | 145 |
| <i>FIGURE 38 U.S. MARKET FOR ACE INHIBITORS, 2009-2016 (\$</i> | |
| <i>MILLIONS)</i> | 145 |
| MARKET SHARES OF INDUSTRY LEADERS IN THE UNITED | |
| STATES..... | 145 |
| PROTON PUMP INHIBITORS | 145 |
| <i>TABLE 66 U.S. MARKET SHARES OF PROTON PUMP INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 146 |
| <i>FIGURE 39 U.S. MARKET SHARES OF PROTON PUMP INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 146 |
| PROTEASE INHIBITORS..... | 147 |
| <i>TABLE 67 U.S. MARKET SHARES OF PROTEASE INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 147 |
| <i>FIGURE 40 U.S. MARKET SHARES OF PROTEASE INHIBITORS</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 147 |
| KINASE INHIBITORS | 148 |
| <i>TABLE 68 U.S. MARKET SHARES OF KINASE INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 148 |
| <i>FIGURE 41 U.S. MARKET SHARES OF KINASE INHIBITORS</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 148 |
| STATINS | 149 |
| <i>TABLE 69 U.S. MARKET SHARES OF STATINS MANUFACTURERS,</i> | |
| <i>2010 (%)</i> | 149 |
| <i>FIGURE 42 U.S. MARKET SHARES OF STATINS MANUFACTURERS,</i> | |
| <i>2010 (%)</i> | 149 |
| AROMATASE INHIBITORS | 150 |
| <i>TABLE 70 U.S. MARKET SHARES OF AROMATASE INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 150 |
| <i>FIGURE 43 U.S. MARKET SHARES OF AROMATASE INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 150 |
| REVERSE TRANSCRIPTASE INHIBITORS..... | 151 |
| <i>TABLE 71 U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE</i> | |
| <i>INHIBITOR MANUFACTURERS, 2010 (%)</i> | 151 |
| <i>FIGURE 44 U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE</i> | |
| <i>INHIBITOR MANUFACTURERS, 2010 (%)</i> | 152 |
| PDE5 INHIBITORS | 152 |
| <i>TABLE 72 U.S. MARKET SHARES OF PDE5 INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 152 |
| <i>FIGURE 45 U.S. MARKET SHARES OF PDE5 MANUFACTURERS,</i> | |
| <i>2010 (%)</i> | 153 |
| NEURAMINIDASE INHIBITORS..... | 153 |

| | |
|--|-----|
| <i>TABLE 73 U.S. MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 153 |
| <i>FIGURE 46 U.S. MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%)</i> | 154 |
| <i>ACE INHIBITORS</i> | 154 |
| <i>TABLE 74 U.S. MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 154 |
| <i>FIGURE 47 U.S. MARKET SHARES OF ACE MANUFACTURERS, 2010 (%)</i> | 155 |
| <i>MARKET BY APPLICATIONS</i> | 155 |
| <i>TABLE 75 U.S. ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016 (\$ MILLIONS)</i> | 156 |
| <i>FIGURE 48 U.S. MARKET INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016 (\$ MILLIONS)</i> | 156 |
| <i>CARDIOVASCULAR (CV) DISEASES</i> | 157 |
| <i>Cardiovascular (CV) Diseases (Continued)</i> | 158 |
| <i>TABLE 76 U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016 (\$ MILLIONS)</i> | 159 |
| <i>FIGURE 49 U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016 (\$ MILLIONS)</i> | 159 |
| <i>GASTROINTESTINAL DISORDERS</i> | 160 |
| <i>TABLE 77 U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016 (\$ MILLIONS)</i> | 160 |
| <i>FIGURE 50 U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016 (\$ MILLIONS)</i> | 161 |
| <i>ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)</i> | 161 |
| <i>TABLE 78 U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 (\$ MILLIONS)</i> | 162 |
| <i>FIGURE 51 U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 (\$ MILLIONS)</i> | 163 |
| <i>HEPATITIS</i> | 163 |
| <i>Hepatitis (Continued)</i> | 164 |
| <i>TABLE 79 U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 (\$ MILLIONS)</i> | 165 |
| <i>FIGURE 52 U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 (\$ MILLIONS)</i> | 165 |
| <i>CANCER</i> | 166 |
| <i>Cancer (Continued)</i> | 167 |
| <i>TABLE 80 U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, THROUGH 2016 (\$ MILLIONS)</i> | 168 |
| <i>FIGURE 53 U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, 2009-2016 (\$ MILLIONS)</i> | 168 |
| <i>ERECTILE DYSFUNCTION</i> | 168 |

| | |
|--|-----|
| TABLE 81 U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016 (\$ MILLIONS)..... | 169 |
| FIGURE 54 U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016 (\$ MILLIONS)..... | 170 |
| OTHERS | 170 |
| TABLE 82 U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 (\$ MILLIONS)..... | 171 |
| FIGURE 55 U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 (\$ MILLIONS)..... | 172 |
| CHAPTER NINE: MARKETS IN EUROPE..... | 173 |
| MARKET ANALYSIS | 173 |
| TABLE 83 EUROPEAN MARKET FOR ENZYME INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 174 |
| FIGURE 56 EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 175 |
| PROTON PUMP INHIBITORS..... | 175 |
| Market Overview | 176 |
| Market Revenue | 177 |
| TABLE 84 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 178 |
| FIGURE 57 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 178 |
| PROTEASE INHIBITORS..... | 178 |
| Market Overview | 179 |
| Market Revenue | 180 |
| TABLE 85 EUROPEAN MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 180 |
| FIGURE 58 EUROPEAN MARKET FOR PROTEASE INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 181 |
| REVERSE TRANSCRIPTASE INHIBITORS..... | 181 |
| Market Overview | 181 |
| Market Revenue | 182 |
| TABLE 86 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 183 |
| FIGURE 59 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 183 |
| KINASE INHIBITORS | 184 |
| Market Overview | 184 |
| Market Overview (Continued)..... | 185 |
| Market Revenue | 186 |
| TABLE 87 EUROPEAN MARKET FOR KINASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)..... | 186 |
| FIGURE 60 EUROPEAN MARKET FOR KINASE INHIBITORS, 2009-2016 (\$ MILLIONS)..... | 186 |

| | |
|--|-----|
| STATINS | 187 |
| Market Overview | 187 |
| Market Revenue | 188 |
| <i>TABLE 88 EUROPEAN MARKET FOR STATINS, THROUGH 2016 (\$</i> | |
| <i>MILLIONS)</i> | 189 |
| <i>FIGURE 61 EUROPEAN MARKET FOR STATINS, 2009-2016 (\$</i> | |
| <i>MILLIONS)</i> | 189 |
| AROMATASE INHIBITORS | 189 |
| Market Overview | 190 |
| Market Revenue | 191 |
| <i>TABLE 89 EUROPEAN MARKET FOR AROMATASE INHIBITORS,</i> | |
| <i>THROUGH 2016 (\$ MILLIONS)</i> | 191 |
| <i>FIGURE 62 EUROPEAN MARKET FOR AROMATASE INHIBITORS,</i> | |
| <i>2009-2016 (\$ MILLIONS)</i> | 191 |
| PDE5 INHIBITORS | 192 |
| Market Overview | 192 |
| Market Revenue | 192 |
| <i>TABLE 90 EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH</i> | |
| <i>2016 (\$ MILLIONS)</i> | 193 |
| <i>FIGURE 63 EUROPEAN MARKET FOR PDE5 INHIBITORS,</i> | |
| <i>THROUGH 2016 (\$ MILLIONS)</i> | 193 |
| NEURAMINIDASE INHIBITORS | 194 |
| Market Overview | 195 |
| Market Revenue | 195 |
| <i>TABLE 91 EUROPEAN MARKET FOR NEURAMINIDASE</i> | |
| <i>INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 195 |
| <i>FIGURE 64 EUROPEAN MARKET FOR NEURAMINIDASE</i> | |
| <i>INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 196 |
| ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS | 196 |
| Market Overview | 196 |
| Market Revenue | 197 |
| <i>TABLE 92 EUROPEAN MARKET FOR ACE INHIBITORS, THROUGH</i> | |
| <i>2016 (\$ MILLIONS)</i> | 197 |
| <i>FIGURE 65 EUROPEAN MARKET FOR ACE INHIBITORS, 2009-2016</i> | |
| <i>(\$ MILLIONS)</i> | 198 |
| MARKET SHARES OF INDUSTRY LEADERS IN EUROPE | 198 |
| PROTON PUMP INHIBITORS | 198 |
| <i>TABLE 93 EUROPEAN MARKET SHARES OF PROTON PUMP</i> | |
| <i>INHIBITOR MANUFACTURERS, 2010 (%)</i> | 199 |
| <i>FIGURE 66 EUROPEAN MARKET SHARES OF PROTON PUMP</i> | |
| <i>INHIBITOR MANUFACTURERS, 2010 (%)</i> | 199 |
| PROTEASE INHIBITORS | 200 |
| <i>TABLE 94 EUROPEAN MARKET SHARES OF PROTEASE INHIBITOR</i> | |
| <i>MANUFACTURERS, 2010 (%)</i> | 200 |

| | |
|--|-----|
| <i>FIGURE 67 EUROPEAN MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010 (%)</i> | 200 |
| <i>KINASE INHIBITORS</i> | 201 |
| <i>TABLE 95 EUROPEAN MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 201 |
| <i>FIGURE 68 EUROPEAN MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010 (%)</i> | 202 |
| <i>STATINS</i> | 202 |
| <i>TABLE 96 EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%)</i> | 203 |
| <i>FIGURE 69 EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%)</i> | 203 |
| <i>AROMATASE INHIBITORS</i> | 203 |
| <i>TABLE 97 EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 204 |
| <i>FIGURE 70 EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 204 |
| <i>REVERSE TRANSCRIPTASE INHIBITORS</i> | 204 |
| <i>TABLE 98 EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 205 |
| <i>FIGURE 71 EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS, 2010 (%)</i> | 205 |
| <i>PDE5 INHIBITORS</i> | 205 |
| <i>TABLE 99 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%)</i> | 206 |
| <i>FIGURE 72 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%)</i> | 206 |
| <i>NEURAMINIDASE INHIBITORS</i> | 206 |
| <i>TABLE 100 EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 207 |
| <i>FIGURE 73 EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 207 |
| <i>ACE INHIBITORS</i> | 207 |
| <i>TABLE 101 EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 208 |
| <i>FIGURE 74 EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 208 |
| <i>MARKET BY APPLICATIONS</i> | 208 |
| <i>TABLE 102 EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016 (\$ MILLIONS)</i> | 209 |
| <i>FIGURE 75 EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016 (\$ MILLIONS)</i> | 210 |

| | |
|---|-----|
| CARDIOVASCULAR (CV) DISEASES | 210 |
| Cardiovascular (CV) Diseases..... | 211 |
| <i>TABLE 103 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>CARDIOVASCULAR DISEASE, THROUGH 2016 (\$ MILLIONS)</i> | 212 |
| <i>FIGURE 76 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>CARDIOVASCULAR DISEASE, 2009-2016 (\$ MILLIONS)</i> | 212 |
| GASTROINTESTINAL DISORDERS | 213 |
| <i>TABLE 104 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>GASTROINTESTINAL DISEASE, THROUGH 2016 (\$ MILLIONS)</i> | 214 |
| <i>FIGURE 77 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>GASTROINTESTINAL DISEASE, 2009-2016 (\$ MILLIONS)</i> | 214 |
| ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)..... | 215 |
| <i>TABLE 105 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>HIV/AIDS, THROUGH 2016 (\$ MILLIONS)</i> | 216 |
| <i>FIGURE 78 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>HIV/AIDS, 2009-2016 (\$ MILLIONS)</i> | 216 |
| CANCER..... | 216 |
| Cancer (Continued)..... | 217 |
| <i>TABLE 106 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>VARIOUS CANCERS, THROUGH 2016 (\$ MILLIONS)</i> | 218 |
| <i>FIGURE 79 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>CANCER, 2009-2016 (\$ MILLIONS)</i> | 219 |
| HEPATITIS | 219 |
| <i>TABLE 107 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>HEPATITIS, THROUGH 2016 (\$ MILLIONS)</i> | 220 |
| <i>FIGURE 80 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>HEPATITIS, 2009-2016 (\$ MILLIONS)</i> | 221 |
| ERECTILE DYSFUNCTION..... | 221 |
| <i>TABLE 108 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>ERECTILE DYSFUNCTION, THROUGH 2016 (\$ MILLIONS)</i> | 222 |
| <i>FIGURE 81 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>ERECTILE DYSFUNCTION, 2009-2016 (\$ MILLIONS)</i> | 222 |
| OTHER DISEASES..... | 222 |
| <i>TABLE 109 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>OTHER DISEASES, THROUGH 2016 (\$ MILLIONS)</i> | 223 |
| <i>FIGURE 82 EUROPEAN MARKET OF ENZYME INHIBITORS IN</i> <i>OTHER DISEASES, 2009-2016 (\$ MILLIONS)</i> | 224 |
| CHAPTER TEN: EMERGING MARKETS..... | 225 |
| MARKET ANALYSIS | 225 |
| MARKET ANALYSIS (CONTINUED)..... | 226 |
| <i>TABLE 110 EMERGING MARKETS FOR ENZYME INHIBITORS,</i> <i>THROUGH 2016 (\$ MILLIONS)</i> | 227 |
| <i>FIGURE 83 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-</i> <i>2016 (\$ MILLIONS)</i> | 227 |

| | |
|---|------------|
| PROTON PUMP INHIBITORS | 228 |
| Market Overview | 228 |
| Market Revenue | 229 |
| <i>TABLE 111 EMERGING MARKETS FOR PROTON PUMP</i> | |
| <i>INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | <i>229</i> |
| <i>FIGURE 84 EMERGING MARKETS FOR PROTON PUMP</i> | |
| <i>INHIBITORS, 2009-2016 (\$ MILLIONS).....</i> | <i>230</i> |
| PROTEASE INHIBITORS..... | 230 |
| Market Overview | 231 |
| Market Revenue | 231 |
| <i>TABLE 112 EMERGING MARKETS FOR PROTEASE INHIBITORS,</i> | |
| <i>THROUGH 2016 (\$ MILLIONS).....</i> | <i>232</i> |
| <i>FIGURE 85 EMERGING MARKETS FOR PROTEASE INHIBITORS,</i> | |
| <i>2009-2016 (\$ MILLIONS).....</i> | <i>232</i> |
| REVERSE TRANSCRIPTASE INHIBITORS..... | 232 |
| Market Overview | 233 |
| Market Revenue | 234 |
| <i>TABLE 113 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE</i> | |
| <i>INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | <i>235</i> |
| <i>FIGURE 86 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE</i> | |
| <i>INHIBITORS, 2009-2016 (\$ MILLIONS).....</i> | <i>235</i> |
| KINASE INHIBITORS | 235 |
| Market Overview | 236 |
| Market Revenue | 237 |
| <i>TABLE 114 EMERGING MARKETS FOR KINASE INHIBITORS,</i> | |
| <i>THROUGH 2016 (\$ MILLIONS).....</i> | <i>237</i> |
| <i>FIGURE 87 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-</i> | |
| <i>2016 (\$ MILLIONS).....</i> | <i>238</i> |
| STATINS | 238 |
| Market Overview | 238 |
| Market Overview (Continued)..... | 239 |
| Market Revenue | 240 |
| <i>TABLE 115 EMERGING MARKETS FOR STATINS, THROUGH 2016 (\$</i> | |
| <i>MILLIONS).....</i> | <i>240</i> |
| <i>FIGURE 88 EMERGING MARKETS FOR STATINS, 2009-2016 (\$</i> | |
| <i>MILLIONS).....</i> | <i>241</i> |
| AROMATASE INHIBITORS | 241 |
| Market Overview | 241 |
| Market Revenue | 242 |
| <i>TABLE 116 EMERGING MARKETS FOR AROMATASE INHIBITORS,</i> | |
| <i>THROUGH 2016 (\$ MILLIONS).....</i> | <i>242</i> |
| <i>FIGURE 89 EMERGING MARKETS FOR AROMATASE INHIBITORS,</i> | |
| <i>2009-2016 (\$ MILLIONS).....</i> | <i>242</i> |
| PDE5 INHIBITORS | 243 |

| | |
|--|-----|
| Market Overview | 243 |
| Market Revenue | 243 |
| <i>TABLE 117 EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 244 |
| <i>FIGURE 90 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 244 |
| NEURAMINIDASE INHIBITORS | 244 |
| Market Overview | 245 |
| Market Revenue | 245 |
| <i>TABLE 118 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 246 |
| <i>FIGURE 91 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 246 |
| ACE INHIBITORS | 246 |
| Market Overview | 247 |
| Market Revenue | 247 |
| <i>TABLE 119 EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i> | 248 |
| <i>FIGURE 92 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016 (\$ MILLIONS)</i> | 248 |
| MARKET SHARES OF INDUSTRY LEADERS IN EMERGING MARKETS | 248 |
| PROTON PUMP INHIBITORS | 248 |
| <i>TABLE 120 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%)</i> | 249 |
| <i>FIGURE 93 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%)</i> | 249 |
| PROTEASE INHIBITORS | 249 |
| <i>TABLE 121 EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 250 |
| <i>FIGURE 94 EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010 (%)</i> | 250 |
| KINASE INHIBITORS | 251 |
| <i>TABLE 122 EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 251 |
| <i>FIGURE 95 EMERGING MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010 (%)</i> | 252 |
| STATINS | 252 |
| <i>TABLE 123 EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%)</i> | 252 |
| <i>FIGURE 96 EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010 (%)</i> | 253 |
| AROMATASE INHIBITORS | 253 |

| | |
|--|-----|
| <i>TABLE 124 EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010 (%)</i> | 253 |
| <i>FIGURE 97 EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 254 |
| REVERSE TRANSCRIPTASE INHIBITORS..... | 254 |
| <i>TABLE 125 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 254 |
| <i>FIGURE 98 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS, 2010 (%)</i> | 255 |
| PDE5 INHIBITORS | 255 |
| <i>TABLE 126 EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%)</i> | 255 |
| <i>FIGURE 99 EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010 (%)</i> | 256 |
| NEURAMINIDASE INHIBITORS | 256 |
| <i>TABLE 127 EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 256 |
| <i>FIGURE 100 EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%)</i> | 257 |
| ACE INHIBITORS | 257 |
| <i>TABLE 128 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 257 |
| <i>FIGURE 101 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%)</i> | 258 |
| MARKET BY APPLICATIONS..... | 258 |
| <i>TABLE 129 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016 (\$ MILLIONS)</i> | 259 |
| <i>FIGURE 102 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS (\$ MILLIONS)</i> | 259 |
| CARDIOVASCULAR (CV) DISEASE | 260 |
| Cardiovascular (CV) Disease (Continued)..... | 261 |
| <i>TABLE 130 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, THROUGH 2016 (\$ MILLIONS)</i> | 262 |
| <i>FIGURE 103 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, 2009-2016 (\$ MILLIONS)</i> | 262 |
| GASTROINTESTINAL DISORDERS | 263 |
| <i>TABLE 131 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, THROUGH 2016 (\$ MILLIONS)</i> | 263 |
| <i>FIGURE 104 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, 2009-2016 (\$ MILLIONS)</i> | 264 |
| ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)..... | 264 |
| <i>TABLE 132 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 (\$ MILLIONS)</i> | 265 |

| | |
|--|---------|
| <i>FIGURE 105 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 (\$ MILLIONS)</i> | 266 |
| HEPATITIS | 266 |
| <i>TABLE 133 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 (\$ MILLIONS)</i> | 267 |
| <i>FIGURE 106 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 (\$ MILLIONS)</i> | 268 |
| CANCER..... | 268 |
| <i>TABLE 134 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016 (\$ MILLIONS)</i> | 269 |
| <i>FIGURE 107 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 (\$ MILLIONS)</i> | 270 |
| ERECTILE DYSFUNCTION (ED)..... | 270 |
| <i>TABLE 135 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016 (\$ MILLIONS)</i> | 271 |
| <i>FIGURE 108 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016 (\$ MILLIONS)</i> | 271 |
| OTHER DISEASES..... | 271 |
| <i>TABLE 136 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH 2016 (\$ MILLIONS)</i> | 272 |
| <i>FIGURE 109 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016 (\$ MILLIONS)</i> | 273 |
| CHAPTER ELEVEN: PATENT ANALYSIS | 274 |
| PATENTS BY YEAR..... | 274 |
| <i>TABLE 137 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008–2012</i> | 275 |
| <i>FIGURE 110 NUMBER OF PATENTS BY YEAR, 2008–2012</i> | 275 |
| <i>FIGURE 111 NUMBER OF PATENTS BY YEAR, 2008–2012 (%)</i> | 276 |
| PATENTS BY TYPE..... | 276 |
| <i>TABLE 138 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012</i> | 277 |
| <i>FIGURE 112 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012</i> | 277 |
| PATENTS BY COMPANY..... | 278 |
| <i>TABLE 139 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008–2012</i> | 278 |
| <i>TABLE 139 (CONTINUED)</i> | 279 |
| PATENTS BY COUNTRY | 280 |
| <i>TABLE 140 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012</i> | 280 |
| <i>FIGURE 113 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012</i> | 281 |
| <i>TABLE 141 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008–2012 (%)</i> | 281 |

| | |
|---|-----|
| <i>FIGURE 114 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012 (%)</i> | 282 |
| PATENTS BY ASSIGNEE | 282 |
| <i>TABLE 142 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008–2012</i> | 282 |
| <i>FIGURE 115 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%)</i> | 283 |
| CHAPTER TWELVE: CURRENT SITUATION | 284 |
| MARKET CONDITIONS..... | 284 |
| UNITED STATES | 284 |
| EUROPE..... | 284 |
| EMERGING MARKETS | 285 |
| TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET | 285 |
| COMPETITION..... | 285 |
| PATENT EXPIRATIONS..... | 285 |
| UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT CLIFF | 286 |
| PATENT CHALLENGES / LEGAL PROCEEDINGS | 286 |
| NEW INDICATIONS APPROVED..... | 286 |
| NEW DRUG APPROVALS | 287 |
| RX- TO- OTC SWITCH | 287 |
| INCREASING NUMBER OF BABY BOOMERS | 288 |
| MERGERS AND ACQUISITIONS AND ALLIANCES..... | 288 |
| DIRECT-TO-CONSUMER ADVERTISING | 289 |
| CHAPTER THIRTEEN: COMPANY PROFILES | 290 |
| ABBOTT LABORATORIES..... | 290 |
| AMGEN INC. | 290 |
| ASTRAZENECA PLC | 291 |
| AUROBINDO PHARMA..... | 291 |
| BAYER HEALTHCARE PHARMACEUTICALS | 292 |
| BOEHRINGER INGELHEIM GMBH | 292 |
| BRISTOL-MYERS SQUIBB..... | 293 |
| CIPLA LTD. | 294 |
| DR. REDDY'S LABORATORIES LTD..... | 294 |
| EISAI INC. | 295 |
| ELI LILLY & CO..... | 295 |
| ENDO PHARMACEUTICALS | 296 |
| GILEAD SCIENCES INC..... | 297 |
| GLAXOSMITHKLINE PLC | 297 |
| GLENMARK GENERICS LTD. | 298 |
| HETERO DRUGS LTD..... | 298 |
| HOFFMAN-LA ROCHE LTD..... | 299 |
| INCYTE CORP..... | 299 |

| | |
|--|-----|
| JOHNSON & JOHNSON | 300 |
| LUPIN PHARMACEUTICALS INC. | 301 |
| MERCK & CO. INC. | 301 |
| MERCK SERONO SA..... | 302 |
| MYLAN LABORATORIES INC. | 303 |
| MYLAN LABORATORIES LTD..... | 303 |
| NOVARTIS AG..... | 304 |
| OSI PHARMACEUTICALS LLC | 305 |
| PAR PHARMACEUTICAL COMPANIES INC. | 305 |
| PFIZER INC..... | 306 |
| RANBAXY LABORATORIES LTD. | 307 |
| ROXANE LABORATORIES LTD. | 307 |
| SANDOZ..... | 308 |
| SANOFI-AVENTIS | 308 |
| SANTARUS INC. | 309 |
| SUN PHARMACEUTICALS | 310 |
| TAKEDA PHARMACEUTICAL CO. LTD..... | 310 |
| TEVA PHARMACEUTICAL INDUSTRIES LTD. | 311 |
| VERTEX PHARMACEUTICALS | 311 |
| VIIV HEALTHCARE | 312 |
| WATSON PHARMACEUTICALS INC. | 312 |
| Watson Pharmaceuticals Inc. (Continued)..... | 313 |
| APPENDIX—ABBREVIATIONS..... | 314 |
| ABBREVIATIONS | 314 |
| ABBREVIATIONS (CONTINUED)..... | 315 |